1 Mole RH, "Whole body irradiation; radiobiology or medicine?" 26 : 234-241, 1953
2 Ngwa W, "Using immunotherapy to boost the abscopal effect" 18 : 313-322, 2018
3 Moriceau G, "Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction" 27 : 240-256, 2015
4 Park B, "The effect of radiation on the immune response to cancers" 15 : 927-943, 2014
5 Abuodeh Y, "Systematic review of case reports on the abscopal effect" 40 : 25-37, 2016
6 Ishiyama H, "Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?" 10 : 196-198, 2012
7 Okwan-Duodu D, "Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma" 38 : 119-125, 2015
8 Eric C. Ko, "Radiotherapy and checkpoint inhibitors: a winning new combination?" SAGE Publications 10 : 175883591876824-, 2018
9 Negi N, "Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ" 37 : 57-68, 2018
10 Weber JS, "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial" 16 : 375-384, 2015
1 Mole RH, "Whole body irradiation; radiobiology or medicine?" 26 : 234-241, 1953
2 Ngwa W, "Using immunotherapy to boost the abscopal effect" 18 : 313-322, 2018
3 Moriceau G, "Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction" 27 : 240-256, 2015
4 Park B, "The effect of radiation on the immune response to cancers" 15 : 927-943, 2014
5 Abuodeh Y, "Systematic review of case reports on the abscopal effect" 40 : 25-37, 2016
6 Ishiyama H, "Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?" 10 : 196-198, 2012
7 Okwan-Duodu D, "Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma" 38 : 119-125, 2015
8 Eric C. Ko, "Radiotherapy and checkpoint inhibitors: a winning new combination?" SAGE Publications 10 : 175883591876824-, 2018
9 Negi N, "Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ" 37 : 57-68, 2018
10 Weber JS, "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial" 16 : 375-384, 2015
11 Eggermont AM, "New drugs in melanoma: it's a whole new world" 47 : 2150-2157, 2011
12 Eichler AF, "Multidisciplinary management of brain metastases" 12 : 884-898, 2007
13 Franchino F, "Mechanisms and therapy for cancer metastasis to the brain" 8 : 161-, 2018
14 Lim SY, "Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma" 123 (123): 2118-2129, 2017
15 Wagle N, "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition" 4 : 61-68, 2014
16 Long GV, "Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib" 36 : 667-673, 2018
17 Golden EB, "Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial" 16 : 795-803, 2015
18 Ott PA, "Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data" 5 : 202-, 2015
19 Long GV, "Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma" 5 : 5694-, 2014
20 Koller KM, "Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone" 18 : 36-42, 2017
21 Kumari A, "Immunomodulatory effects of radiation: what is next for cancer therapy?" 12 : 239-256, 2016
22 Muldoon LL, "Immunologic privilege in the central nervous system and the blood-brain barrier" 33 : 13-21, 2013
23 Beaver JA, "FDA approval of nivolumab for the first-line treatment of patients with BRAF(V600) wild-type unresectable or metastatic melanoma" 23 : 3479-3483, 2017
24 Barone A, "FDA Approval Summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma" 23 : 5661-5665, 2017
25 Hazarika M, "FDA Approval Summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab" 23 : 3484-3488, 2017
26 Chuk MK, "FDA Approval Summary: accelerated approval of pembrolizumab for secondline treatment of Metastatic Melanoma" 23 : 5666-5670, 2017
27 Long GV, "Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study" 28 : 1631-1639, 2017
28 Long GV, "Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAFmutant melanoma: a multicentre, double-blind, phase 3randomised controlled trial" 386 : 444-451, 2015
29 Rausch MP, "Cutaneous melanoma: etiology and therapy" Codon Publications 2017
30 Chicas-Sett R, "Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review" 9 : 5-11, 2017
31 Ascierto PA, "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial" 17 : 1248-1260, 2016
32 Johnson DB, "Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms" 51 : 2792-2799, 2015
33 Brix N, "Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences" 280 : 249-279, 2017
34 Grimaldi AM, "Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy" 3 : e28780-, 2014
35 Siva S, "Abscopal effects of radiation therapy: a clinical review for the radiobiologist" 356 : 82-90, 2015
36 Chandra RA, "A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab" 4 : e1046028-, 2015
37 Hiniker SM, "A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma" 96 : 578-588, 2016